FDA Grants Interchangeable Designation to Fresenius Kabi’s biosimilar Otulfi
May 19, 2025
Fresenius Kabi, an operating company of Fresenius, and Formycon AG, announced that the U.S. Food and Drug Administration (FDA) designated Otulfi (ustekinumab-aauz) as an interchangeable